#USA #Q3 2025 #TransMedics #Andover #organ transplant

TransMedics Reports Q3 2025 Financial Results

TransMedics Group, Inc. (Nasdaq: TMDX), a pioneering medical technology company based in Andover, Massachusetts, has announced its financial outcomes for the third quarter of 2025, ending September 30. The company, renowned for its innovative contributions to organ transplant therapy, has reported a total revenue of $143.8 million, marking a 32% increase from $108.8 million in the same period of the previous year. This growth reflects a substantial rise in the utilization of the Organ Care System (OCS), particularly within the National OCS Program (NOP).

Financial Highlights

In the latest quarter, TransMedics reported a net income of $24.3 million, equating to $0.66 per diluted share, a remarkable increase from $4.2 million in Q3 2024. The company’s gross margin improved to 59%, up from 56% year-over-year, evidencing efficient cost management aligned with increasing revenues.

TransMedics expanded its capabilities in organ transport, owning 21 aircraft as of September 30, with plans to increase the count to 22 by October 29, 2025. A notable development is their strategic collaboration with Mercedes-Benz Group AG. This partnership will launch a fleet of modern Mercedes-Benz V-Class vehicles exclusively designated for organ transportation across Italy. This initiative underscores TransMedics’ commitment to enhancing logistical efficiency in organ transplant services.

Focus on Growth Initiatives

Waleed Hassanein, M.D., President and CEO of TransMedics, stated, “Overall, we are very pleased with our third quarter performance and the significant progress our team is making across multiple growth initiatives in the U.S. and globally. Importantly, we are now laser-focused on ending 2025 on a strong note while creating the foundation for another robust growth year in 2026.” The emphasis on growth reflects TransMedics’ strategic positioning, bolstered by their advanced OCS™ technology and proprietary digital ecosystem, NOP Connect™.

This technological framework allows TransMedics to deliver unparalleled lifesaving solutions to transplant markets worldwide. The organization's bold target of performing 10,000 NOP transplants by 2028 is supported by the recent progress in operational capacity and market reach.

Financial Outlook

TransMedics has adjusted its full-year 2025 revenue guidance to between $595 million to $605 million, up from previous estimates. This represents a 36% growth at the midpoint compared to last year, positioning the company for continued expansion in the upcoming quarters.

Investors can expect a conference call scheduled for 4:30 p.m. ET on October 29, 2025, where the management team will discuss these results in greater detail. Interested parties may join by calling (844) 676-6010 for domestic or (412) 634-6944 for international access.

TransMedics continues to be a trailblazer in the field of organ transplant solutions, and these recent results serve not only as a reflection of past successes but as a promise of future innovations in medical technology aimed at saving lives.

About TransMedics Group, Inc.

Founded to tackle the pressing need for better organ transplantation solutions, TransMedics leads globally in portable extracorporeal warm perfusion. Their advancements not only help preserve organ viability and quality prior to transplant but also aim to increase the overall availability of donor organs for patients fighting end-stage organ failure.